Arnatar Therapeutics specializes in advanced RNA targeting technologies, particularly focusing on antisense molecules to address diseases caused by mutations or abnormal RNA expression. Their approach involves designing antisense molecules that can specifically target and modulate the function of RNA, which allows for the rational development of personalized medicines. The company aims to harness RNA biology to create innovative treatments for patients with unmet medical needs, emphasizing their commitment to advancing cutting-edge antisense technologies, including small interfering RNAs (siRNA) and antisense oligonucleotides (ASOs).

The company's advanced antisense platform utilizes the principles of Watson-Crick base-pairing to exert pharmacological effects by modulating target RNA levels. siRNAs operate through RNA interference, a natural cellular mechanism that silences gene expression, while ASOs offer greater versatility, allowing for the alteration of RNA splicing and expression levels. Arnatar Therapeutics' technology enables programmable control over the potency, onset, and duration of action for both RNAi and ASO platforms, providing opportunities to treat a wide range of diseases affecting both liver and extra-hepatic organs, including both common and rare conditions.

United States

Harnessing the power of RNA biology to find treatments for patients with unmet medical needs. Advance and utilize the cutting edge antisense technology (siRNA and ASO) to discover and develop next generation medicines for both large and rare disease indications.

Arnatar Therapeutics

Company Details